2 ASX penny stocks to consider buying while their prices are this cheap

Analysts think high rewards could be on offer from these high risk stocks.

| More on:
a man looks down at his phone with a look of happy surprise on his face as though he is thrilled with good news.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors with a high risk tolerance might want to consider adding the two ASX penny stocks in this article to a balanced portfolio.

That's because although they are high risk investments, they have the potential to offer high rewards.

Let's take a closer look at them and see why analysts are tipping them as buys right now:

Pointsbet Holdings Ltd (ASX: PBH)

This sports betting company has been given the thumbs up by analysts at Bell Potter.

It thinks Pointsbet could be an ASX penny stock to buy based on its current valuation. The broker feels that the market is undervaluing its operations and sees it as a potential takeover target for a bigger player. It explains:

We determine our price target for PointsBet through a sum-of-the-parts (SOTP) and there is no change in the $0.63 valuation. The components of this valuation are $150m for the Australian business ($0.46/share), $25m for the Canadian business ($0.08/share) and $30m in corporate cash ($0.09/share). We note we ascribe no value for the Banach technology which PointsBet can continue to use for in-play betting in Canada and, to a lesser extent, Australia. We also believe PointsBet is a potential takeover target given its market position (fifth largest in Australia), simplified structure (Australia and Canada), proprietary technology and good Balance Sheet.

Bell Potter has a buy rating and 63 cents price target on its shares. Based on its current share price of 50.5 cents, this implies potential upside of 25% for investors over the next 12 months.

PYC Therapeutics Ltd (ASX: PYC)

Another ASX penny stock to look at according to Bell Potter is PYC Therapeutics. It is clinical-stage biotechnology company developing multiple drug candidates for rare inherited diseases.

The broker highlights that PYC recently reported highly encouraging first clinical data for its lead drug candidate, VP-001, in patients with a rare form of blinding eye disease. It feels that the positive readout provides significant validation for the individual asset and broader PYC platform. It also feels that successful readouts in other phase 1/2 trials would provide considerable de-risking.

In light of this, this month Bell Potter initiated coverage on the ASX penny stock with a speculative buy rating and 17 cents price target. This implies potential upside of 70% for investors from current levels. The broker commented:

We initiate coverage of PYC with a speculative BUY recommendation and $0.17 valuation. Pro-forma cash balance was ~$84m as at 31 March 2024, providing runway into 2H CY25 to achieve the above-mentioned Phase 1/2 clinical trial readouts. PYC have multiple shots on goal with three highly promising drug candidates for rare diseases. We also see value in the company's internal platform and potential to continually generate differentiated RNA therapeutics for inherited diseases.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended PointsBet. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Small Cap Shares

A young boy wearing a hat, sunnies and striped singlet looks fierce and flexes his arm in victory.
Small Cap Shares

Why this ASX small-cap stock has significant potential

This business is delivering significant growth.

Read more »

Five young boys wearing small caps sit on a bench together watching a baseball game.
Small Cap Shares

5 ASX small-cap shares that screamed 114% to 362% higher in FY25

Here are some examples of ASX small-cap shares that experienced outstanding price growth in FY25.

Read more »

Three young people in business attire sit around a desk and discuss.
Small Cap Shares

Tiny tech: 3 ASX small-cap shares with new ratings

Toby Grimm of Baker Young and Peter Day of Sequoia Wealth Management share their new ratings.

Read more »

Three people in a corporate office pour over a tablet, ready to invest.
Small Cap Shares

Hidden gems: Experts name 3 ASX small-cap shares to buy now

One of these ASX small-cap shares has risen by a staggering 1,687% over the past 12 months.

Read more »

A woman presenting company news to investors looks back at the camera and smiles.
Small Cap Shares

These ASX small cap shares could be tomorrow's blue chips

Analysts think these small caps could be great picks right now.

Read more »

A elder man and woman lean over their balcony with a cuppa, indicating share rpice movement for ASX retirement shares
Small Cap Shares

Why I think this ASX small-cap stock is a bargain at 58 cents

This stock looks like a great buy, in my opinion.

Read more »

A young boy wearing a hat, sunnies and striped singlet looks fierce and flexes his arm in victory.
Small Cap Shares

Forget CBA shares. What about small-cap ASX financial shares?

Analysts discuss 2 small-cap ASX financial shares that are up by more than 40% in 2025.

Read more »

A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face over these rising Tassal share price
Small Cap Shares

Bell Potter says this small cap ASX stock can rocket 100%

The broker expects big returns from this small cap. Let's find out why it is bullish.

Read more »